73 related articles for article (PubMed ID: 29330395)
1. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.
Olivieri J; Attolico I; Nuccorini R; Pascale SP; Chiarucci M; Poiani M; Corradini P; Farina L; Gaidano G; Nassi L; Sica S; Piccirillo N; Pioltelli PE; Martino M; Moscato T; Pini M; Zallio F; Ciceri F; Marktel S; Mengarelli A; Musto P; Capria S; Merli F; Codeluppi K; Mele G; Lanza F; Specchia G; Pastore D; Milone G; Saraceni F; Di Nardo E; Perseghin P; Olivieri A
Bone Marrow Transplant; 2018 Apr; 53(4):461-473. PubMed ID: 29330395
[TBL] [Abstract][Full Text] [Related]
2. Poor mobilizer: a retrospective study on proven and predicted incidence according to GITMO criteria.
Piccirillo N; Vacca M; Lanti A; Ipsevich F; Maresca M; Fiorelli E; Bianchi M; Adorno G; Pierelli L; Majolino I; Leone G; Zini G
Transfus Apher Sci; 2012 Oct; 47(2):217-21. PubMed ID: 22784631
[TBL] [Abstract][Full Text] [Related]
3. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.
Sahin U; Demirer T
J Clin Apher; 2018 Jun; 33(3):357-370. PubMed ID: 28980709
[TBL] [Abstract][Full Text] [Related]
4. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield.
Duong HK; Bolwell BJ; Rybicki L; Koo A; Hsi ED; Figueroa P; Dean R; Pohlman B; Kalaycio M; Andresen S; Sobecks R; Copelan E
J Clin Apher; 2011; 26(3):111-5. PubMed ID: 21647951
[TBL] [Abstract][Full Text] [Related]
5. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.
Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM
Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329
[TBL] [Abstract][Full Text] [Related]
7. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.
Costa LJ; Nista EJ; Buadi FK; Lacy MQ; Dispenzieri A; Kramer CP; Edwards KH; Kang Y; Gertz MA; Stuart RK; Kumar S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):222-8. PubMed ID: 24211319
[TBL] [Abstract][Full Text] [Related]
8. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
9. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.
Rossi G; Skert C; Morello E; Almici C; Arcaini L; Basilico C; Cavalli L; Botto B; Castelli A; Pica G; Ripamonti F; Salvi F; Carella AM; Gaidano G; Levis A; Nosari A; Russo D; Vitolo U
Hematol Oncol; 2015 Sep; 33(3):125-32. PubMed ID: 24890497
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study.
Han X; Ma L; Zhao L; He X; Liu P; Zhou S; Yang J; Qin Y; Yang S; Yao J; Shi Y
J Clin Apher; 2012; 27(2):64-74. PubMed ID: 22298390
[TBL] [Abstract][Full Text] [Related]
11. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Peled A; Abraham M; Avivi I; Rowe JM; Beider K; Wald H; Tiomkin L; Ribakovsky L; Riback Y; Ramati Y; Aviel S; Galun E; Shaw HL; Eizenberg O; Hardan I; Shimoni A; Nagler A
Clin Cancer Res; 2014 Jan; 20(2):469-79. PubMed ID: 24246358
[TBL] [Abstract][Full Text] [Related]
12. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
13. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
14. The more, the less: age and chemotherapy load are predictive of poor stem cell mobilization in patients with hematologic malignancies.
Yang SM; Chen H; Chen YH; Zhu HH; Zhao T; Liu KY
Chin Med J (Engl); 2012 Feb; 125(4):593-8. PubMed ID: 22490480
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for a poor hematopoietic stem cell mobilization.
Donmez A; Yilmaz F; Gokmen N; Tombuloglu M
Transfus Apher Sci; 2013 Dec; 49(3):485-8. PubMed ID: 23693121
[TBL] [Abstract][Full Text] [Related]
18. [Clinical analysis of peripheral blood stem cell mobilization regimens in autologous transplantation for treating non-Hodgkin's lymphoma].
Huang SY; Liu L; Hao MW; Yin DD; Wu YL; Chen RA; Li GH; Lui Q; Wang JC; He H; Liang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1415-8. PubMed ID: 22169294
[TBL] [Abstract][Full Text] [Related]
19. Poor mobilizer and its countermeasures.
Miyazaki K; Suzuki K
Transfus Apher Sci; 2018 Oct; 57(5):623-627. PubMed ID: 30268541
[TBL] [Abstract][Full Text] [Related]
20. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
